Tanzania Expands Immunization Program to Include Pfizer Inc. (PFE)'s Prevenar 13 for Prevention of Pneumococcal Disease
12/5/2012 10:13:03 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) welcomes today’s announcement from the GAVI Alliance that Pfizer’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), is now included in the expanded pediatric immunization program in Tanzania. Pneumococcal disease is one of the leading causes of vaccine-preventable deaths worldwide in children younger than 5 years of age and results in more than one out of every five deaths in children younger than 5 years of age in Tanzania. The availability of Prevenar 13 in Tanzania is made possible by the Advance Market Commitment (AMC), an innovative funding mechanism that provides newer vaccines on a sustainable, affordable and accelerated basis to the world’s poorest countries. In just two years, 20 countries, including Tanzania, have introduced Prevenar 13 into their immunization programs as part of the AMC. This potentially lifesaving vaccine is being offered to help protect an estimated 10.5 million infants and children in these developing countries from pneumococcal pneumonia and invasive disease caused by the serotypes in the vaccine.